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Abstract
Depression is one of the major contributors to the Total Disease Burden and afflicts about one-sixth of Western
populations. One of the most effective treatments for depression focuses upon analysis of causal chains in overt
behaviour, but does not include brain-related phenomena as steps along these causal pathways. Recent research
findings regarding the neurobiological concomitants of depressive behaviour suggest a sequence of structural and
functional alterations to the brain which may also produce a beneficial outcome for the depressed individual–that
of adaptive withdrawal from uncontrollable aversive stressors. Linking these brain-based explanations to models of
observable contingencies for depressive behaviour can provide a comprehensive explanation of how depressive
behaviour occurs and why it persists in many patients.
Background
Principally via its harmful effects on health, relationships
and cognitive performance [1-4], depression is the prin-
cipal contributor to the Total Disease Burden [5] and
predicted to become the second leading cause of mental
illness by 2020 [6,7]. As an indication of the significance
of this problem, it has been shown that depression
poses as great a risk for mortality as does smoking, even
when controlling for blood pressure, alcohol intake, cho-
lesterol and social status [8]. The incidence of having a
major depressive episode during one’s lifetime is 17% in
the USA and 13% in Europe [9-11], suggesting that
nearly one in five people may suffer this disorder.
Together, these data argue for the urgency of research
into effective treatments for depression, particularly
those that are based upon explanations of depression
that encompass both externally-observable behaviour
and also brain function.
Treatment of depression
Both pharmacological and psychological treatments
have been shown to be effective with various popula-
tions of depressed persons [12,13], with some data sug-
gesting a reciprocal relationship between these two
approaches [14,15]. One form of psychological treatment
that has a strong evidence basis and which is relevant to
a discussion of the links between brain and behaviour in
explaining the ‘causality’ of depression is that which is
commonly referred to as “Behavioural Functional Analy-
sis”. This process underlies many successful psychologi-
cal treatments [e.g., 16, 17-22], and is characterised by a
focus upon the purpose or outcome of behaviour for the
organism exhibiting it [21], information that is acquired
by examining the antecedents and consequences of a
particular behaviour and determining the links between
these two aspects. As well as being successful with mild
to moderate depression, there are also data which sup-
port the use of some of these functional analytic
approaches with Major Depressive Disorder (MDD)
[23], indicating that this form of psychotherapy may be
at least as effective as antidepressant medication for
reducing the symptoms of acute depression [24-26].
This process of analysing the antecedents and conse-
quences of overt behaviours as causal vectors for
depression is the central theme of Behavioural Func-
tional Analysis, and may reveal the outcomes of depres-
sive behaviour for the individual exhibiting it [27,28].
For example, depressive behaviour may (unwittingly) be
negatively reinforced by avoidance of, or escape from,
threats, and positively reinforced by social attention and
help from peers, relatives or (in the case of humans)
professionals who focus upon the depressed individual’s
suffering and attempt to alleviate it by various means
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[29]. These consequences for depressive behaviour may
provide powerful contingencies for maintenance of the
depressive symptomatology, at least for a period of time.
As noted 150 years ago by Charles Darwin (p. 51):
Pain or suffering of any kind, if long continued,
causes depression and lessens the power of action;
yet, it is well adapted to make a creature guard itself
against any great or sudden evil” [30].
Thus, depressive behaviour may provide a (temporary)
benefit for individuals when they encounter uncontrolla-
bly aversive environments, and this model is congruent
with the hypothesis advanced several decades ago by
Ferster [31], Dougher and Hackbert [32] and most
recently elaborated by Kanter, Busch, Weeks, and
Landes [33] that depressive symptomatology falls within
the spectrum of withdrawal from contact with an
uncontrollably aversive environment [29]. Although the
“adaptive” nature of that withdrawal may become mala-
daptive over time, the initial function of the depressive
behaviours is adaptive for the person exhibiting it.
This perspective is parallel to the notion of “sickness
behaviour” in humans and other animals as postulated
by Dantzer, O’Connor et al. [34], who identified symp-
toms such as feeling feverish and nauseous, experiencing
a lack of appetite, sleep disturbance, loss of interest in
social and physical environments, anhedonia, and being
easily fatigued, as normal responses to infection and
which are triggered by pro-inflammatory cytokines such
as IL-1b and TNF-a. That is, as well as coordinating the
local inflammatory response to infection, IL-1b and
TNF-a also act on receptors spread throughout several
regions of the brain (e.g., dentate gyrus, pyramidal cell
layers of the hippocampus, anterior pituitary gland,
hypothalamus and others [35,36]) to cause these sick-
ness behaviours. In terms of their function, these sick-
ness behaviours help infected individuals cope with their
illness by changing their perceptions of their state and
their reactions to it.
However, in some cases, those sickness behaviours
may be so severe as to constitute the necessary sympto-
matology for a diagnosis of MDD by way of the social
withdrawal that characterizes cytokine-induced sickness
behaviour and which also underlies all depressive symp-
tomatology [29]. Dantzer, et al. reported that adminis-
tration of IL-1b or TNF-a to rats induced sickness
behaviour such as withdrawal from social activity,
reduced motor behaviour, reduced water and food
intake, increased fatigue, altered cognition and changed
sleep patterns. The rats “stay in a corner of their cage in
hunched posture” (p. 48), reminiscent of the behaviour
of many humans with MDD [37]. When applied to the
specific MDD symptoms of sadness, anhedonia, sleep
disturbance, appetite change and cognitive impairment,
these symptoms may be seen to represent a biological
response pattern that translates into the psychological
behaviours of low self-esteem, hopelessness and help-
lessness. Although these may be unpleasant, this with-
drawal from aversive stimuli and environments that
characterises depression has been described as “adap-
tive” because it also reduces the quantum of noxious sti-
muli to which the organism is exposed [38,39]. An
important aspect of the mechanism underlying this
withdrawal is the conviction on the part of depressive
individuals that they have no real control over the
unpleasant experience that is occurring to them [38,39]
and therefore are left with a single response that will
reduce distress—withdrawal from the environment that
is causing it. In this way (and as indicated by Darwin),
depression may perform a valuable function for the
depressed individual [40,41] by reducing unpleasantness
in the only way possible at that time.
However, psychological treatments for depression that
use Functional Analysis (to at least some extent) have
focussed almost exclusively upon the readily observable
(i.e., overt) environmental antecedents and consequences
for depressive behaviour. Explanations based upon those
data alone are incomplete because they do not describe
the less-easily observed neurobiological links between the
organism experiencing the genetic and environmental
stimuli and the later emergence of depressive behaviour.
A description of those neurobiological links to depression
would not only provide a more complete and logical
description of the development of depressive behaviour as
a typical response to overpowering and aversive environ-
mental stress, it could also inform treatment of depression.
From a biological standpoint, while some of the ante-
cedents for depression are genetic [42-45], one of the
strongest predictors of depression is stress in the form
of excessive demanding challenges across a range of
areas [46]. Stress acts through a variety of physiological
causal pathways which may undermine an individual’s
ability to withstand it [47,48] so that, over prolonged
time, depressive symptoms occur. Those causal path-
ways include not only the form of the externally-obser-
vable behaviour, the function of that behaviour (in terms
of outcomes gained by the organism exhibiting it), but
also a consideration of how brain responses act in con-
cert with those behaviours to produce an overall valued
outcome for the depressed individual.
Therefore, this paper addresses the issue of linking
depressive behaviour with brain function and (a)
describes the neurobiological steps between onset of an
environmental stressor and the later development of
depressive behaviour, (b) explains how these steps func-
tion for the benefit of the depressed individual, and (c)
raises some implications for treatment options.
Sharpley and Bitsika Behavioral and Brain Functions 2010, 6:73
http://www.behavioralandbrainfunctions.com/content/6/1/73
Page 2 of 9
The neurobiology of depression
There are several subtypes of depression, but the most
common is unipolar depression, characterised by the
presence of anhedonia and general sadness, plus a range
of other cognitive, physical or emotional symptoms [37].
Some of the brain-based aspects of depression link with
its psychological symptoms, indicating that this disorder
needs to be considered from a unified perspective. For
example, depressed patients can exhibit: depressed
mood, which may be associated with dysfunction of the
activity of the left dorsolateral prefrontal cortex [49];
excessive guilt and hopelessness, which is linked with
dysfunction of the hypothalamic-pituitary-adrenal (HPA)
axis [50-53]; psychomotor agitation, loss of weight and
sleep problems, perhaps reflecting abnormalities in the
function of the thyroid axis [54]; and disturbances to
Random Eye-Movement sleep, commonly caused by
changes to circadian rhythms [55].
Most brain functions rely upon the presence of various
neurotransmitters. Reduced availability of those neuro-
transmitters causes impaired cognitive performance and
may lead to depression [56]. This process has been
described as the “monoamine hypothesis” because it
focuses upon the reduced presence of monoamine neuro-
transmitters in depressed persons, a state that is brought
about via the degrading actions of monoamine oxidases
in the synaptic cleft [56]. By applying anti-oxidase agents
in the form of antidepressant medication, levels of mono-
amine neurotransmitters may be restored [57,58]. Seroto-
nin, noradrenalin and dopamine are particularly
important monoamine neurotransmitters that have been
inculcated in depression [56]. Serotonin (or 5-HT) has
the largest cohesive neurotransmitter system in the brain
and innervates all brain areas [59]. Changes to serotonin
have been shown to influence the core behavioural and
somatic functions that underlie depression, such as appe-
tite, sleep, sex, pain response, body temperature and cir-
cadian rhythm [60], and post-mortem studies indicate
lowered levels of serotonin in the brains of depressed
patients [61-63]. Noradrenalin is also a major neurotrans-
mitter, with noradrenergic neurons spreading from the
brain stem to almost all brain areas and modulating the
function of the prefrontal cortex (which uses working
memory to regulate behaviour and attention), as well as
having an important role in the acquisition of emotion-
ally-arousing memories [59]. Dopamine modulates activ-
ity in brain areas involved with reward and motivation,
working memory and attention [64], and reduced dopa-
mine has also been inculcated in the development of
depression [65]. As may be expected, serotonin, noradre-
nalin and dopamine are primary targets for pharmacolo-
gical treatments for depression.
Genetic bases for the reduced functionality of seroto-
nin [66] and dopamine [67] have been established.
However, these genetic influences do not operate in a
vacuum, and the interaction of environmental stress
with genes has been shown to be reciprocal [68]. Ado-
lescent depression develops via the experience of aver-
sive environmental events and chronic stress during
childhood, acting through prolonged HPA activation as
indicated by elevated cortisol [69,70] in those individuals
who carry particular genes that are up-regulated by the
adverse experiences of childhood. For example, early life
adversity decreases expression by the gene for Brain-
Derived Neurotrophic Factor, which mediates neural
plasticity in the prefrontal cortex (PFC) and hippocam-
pus [71]. Interactions between environmental events and
genetic predisposition to depression reduce neurogenesis
in the hippocampus (an area which is centrally involved
in the storage and accessing of memories that underlie
emotional expression), thereby contributing to lowered
mood and depression [46]. Taken together, these data
provide support for the “Diasthesis-Stress hypothesis”
[72,73], under which interactions between the environ-
ment and genes lead to associated neurobiological and
structural changes in the brain that are linked to depres-
sion [74-76]. The major pathway through which envir-
onmental adversity leads to gene-linked changes in
neurotransmitter function, brain structure and thence
depression, is the HPA axis.
How the HPA axis links genes, environmental
stress and depressive behaviour
Hyperesponsivity of the HPA axis under stressful envir-
onmental conditions has been associated with depres-
sion in several studies [e.g., [50-53]]. When highly
activated, the HPA axis produces elevated serum corti-
sol, leading to hypercortisolaemia, which can cause
changes to those regions of the brain that are associated
with cognitive processing of how threatening a particu-
lar environmental demand may be to the individual and
how that threat might be dealt with (i.e., PFC and hip-
pocampus), plus those regions which are centrally asso-
ciated with intensifying emotional responses (i.e.,
amygdala) [77]. Specifically, these hypercortisolaemic
effects include dendritic branching and neurogenesis
which produce increases in the volume of the amygdala
[78], and cell apoptosis which decreases the volumes of
the PFC [79] and hippocampus [80]. There are also
alterations to the connectivity of those regions of the
brain, for example between the amygdala and the PFC
[81] and between the amygdala and the hippocampus
[82]. These organic changes to the brain have been
linked to the eventual development of those withdrawal
behaviours that underlie depressive symptomatology
[29,33]. Those brain region and interconnectivity
changes have been shown to be a direct outcome
of hypercortisolaemia, and this pathway between
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environmental stressor-induced hyperactivation of the
HPA axis and depression represents the neurobiological
link between those stressors and the depressive sympto-
matology that is described in behavioural accounts of
depression.
The accepted symptomatologies of depression (i.e.,
DSM, ICD) highlight the specific presence of apathy and
anhedonia, which are localised to the reward circuits in
the limbic system that are heavily reliant on dopamine
[83], leading Nestler, et al. [76] to call that limbic
reward system the “neural circuitry of depression” (p.
16). For example, amygdala blood flow increases, but
PFC blood flow decreases, in depressed patients com-
pared to non-depressed controls [84], supporting the
finding that increases in amygdala function are related
to depressive state [85]. In addition to this emotional
aspect of depression, and because the PFC is a key area
for motivation to change or adapt to demanding envir-
onments, damage to the PFC also impairs these resili-
ence-oriented abilities, and apathy may develop. As
mentioned above, apathy is the central symptom of
depression [86], and prevents depressed individuals from
taking action to reduce their unhappiness via more pro-
ductive problem-solving and lifestyle strategies [37].
Thus, impairment of the PFC is directly linked to this
key symptom of depression [87].
These structural changes to the amygdala, PFC and
hippocampus also induce elevated anxiety behaviour,
which may then instigate even greater elevation of
hypothalamic responses to stress. When the individual is
threatened, the activation of the amygdala stimulates the
hypothalamus for fight-or-flight responses. By contrast,
the hippocampus has an inhibitory effect upon the
hypothalamus [88], principally via the involvement of its
ventral region in inhibition of the sympathetic nervous
system (SNS) and subsequent reduction of anxiety beha-
viours [89]. While anxiety may occur alone, it is often
comorbid with depression [90], and there is also major
overlap in the symptomatology for both disorders [91].
These links between hippocampal inhibition of anxiety
and the amygdaloid activation of fear via hypothalamic
neuroendocrine secretions may represent a “balance” of
efforts by these two regions that has the effect of allow-
ing the individual to manage threat effectively [92].
When that balance is disturbed by alterations to the hip-
pocampus and amygdala (and their comparative influ-
ence on the hypothalamus), disturbances in mood
follow, contributing to the likelihood of clinical
depression.
These findings suggest a model of depression in which
a circuit including the PFC, amygdala and hippocampus
influences not only mood regulation, but also learning
and contextual memory processes [88]. Specifically, dur-
ing major depression the ventromedial prefrontal cortex
(VMPFC) and lateral orbital prefrontal cortex (LOPFC)
are hyperactivated and the dorsolateral prefrontal cortex
(DPFC) is hypoactivated [93,94]. These changes are con-
sistent with the symptoms of major depression because
hyperactivation of the VMPFC is associated with sensi-
tivity to pain, anxiety, depressive rumination and ten-
sion, while hypoactivity of the DPFC is associated with
psychomotor retardation, apathy, and deficits in working
memory and attention [88]. Studies of the connectivity
between these areas have also suggested that decreased
communication between the amygdala and anterior cin-
gulate complex (ACC) occurs in major depression [95].
Because the ACC acts to inhibit emotional regulation
[89], decreases in communication between it and the
amygdala could be involved in the irregularity of mood
that is another symptom of depression [88].
These details are important in forming a causal chain
that links environmental stressors to depressive beha-
viour because, when connectivity is disrupted between
the integrative and executive functions of the lateral
orbital PFC, rostral PFC, medial PFC, dorsolateral PFC
and dorsal ACC on one hand, and the emotional/visc-
eral functions of the ventral ACC and ventral medial
PFC, plus the hippocampus, amygdala and nucleus
accumbens on the other hand, the brain undergoes a
decrease in regulatory feedback from the former
“rational” regions to the latter “emotional” regions [92].
This allows the latter to dominate control of the
hypothalamus and consequent neuroendocrine activity,
leading to further stress responses and SNS dominance
[77], plus increases in fear and consequent withdrawal
by the fearful/depressed individual from their physical
and social environment [29,33].
Explaining functional outcomes of depression
from a behavioural-neurobiological perspective
As indicated above, the amygdala enlarges and the PFC
and hippocampus shrink either before or during the
initial stages of depression, producing a more emotion-
oriented response pattern in the depressed individual,
principally via elevated activation of the HPA axis,
hypercortisolaemia, increased hypothalamic activity and
downstream increases in SNS activity. Although this
emotionality might initially appear to be at odds with
the relatively “flat” affect that is symptomatic of depres-
sion, it may more easily fit within the early stage of
depression, when the patient is faced with uncontrolla-
ble aversive environmental events. When faced with that
kind of insurmountable environmental stressor, the rela-
tive usefulness of completely rational problem-solving
strategies is probably low, simply because of the power-
lessness experienced by the depressed individual when
they consider their situation rationally. That is, com-
pared to emotional responses that may enhance the
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individual’s likelihood of (even by chance) finding a
strategy out of the uncontrollable aversive situation they
are in, rational thinking may be less likely to be selected
by environmental pressures. In addition, these heigh-
tened emotional responses in the face of uncontrollable
aversive stressors may result in the depressed individual
becoming extremely frightened and even behaviourally
“freezing” or withdrawing, and thereby avoiding further
unwanted aversive outcomes. This phenomenon of
“freezing” is common among mammals as a response to
a predator and has a functional value in that it shows
submission and hence may cause the predator to cease
attacking [96,97]. Freezing may also perfor a valuable
function because many predators’ actions are triggered
by movement, and they may lose interest when the prey
remains motionless for some time, thus conveying a sur-
vival advantage upon the frozen prey [98]. Additionally,
some predators do not eat dead meat and may refrain
from eating prey that appears to be dead (i.e., immobile)
[99]. Similar freezing behaviour has been reported in
humans when faced with rape [100] and airline disasters
[101], and has been described as “an evolutionary-based
fear response” [102].
However, although several authors have described
depression as “evolutionary” in that it has evolved to
perform the functions of (1) withdrawing from
uncontrollable aversive stressors and allowing the
depressed individual time to analyse the stressful situa-
tion they find themselves in, and (2) eliciting assistance
from partners and close others [102,103], this model is
not without its critics [104,105] and may also be mis-
named on biological grounds because depressed indivi-
duals do not possess any visible reproductive advantage,
nor do their offspring [106]. More accurately, depression
might be considered to serve the immediate adaptive
function of withdrawal in the face of uncontrollable
aversive environmental stressors, i.e., it performs a func-
tion for the depressed person at the time of the stressor.
That function may include reduction in the intensity of
the environmental stressor’s effect upon them, provision
of time for reflection on future responses to the stressor,
allowing time for the stressor to pass, and as a passive
invitation to others to take some responsibility for the
depressed individual’s welfare. In more modern times,
depression may also serve the individual by providing
intense nurturing in the form of psychotherapy [107],
reduction of the organic unpleasantness associated with
depression via antidepressant medication [108], reduc-
tion of workload via formal sick-leave [109], and wider
social support from family and friends.
When viewed from this perspective, the neurobiolo-
gical responses of: (i) elevated HPA axis activation in
response to overwhelming stressors, followed by conse-
quent hypercortisolaemia, which causes (ii) structural
alterations to the amygdala (enlargement) and PFC and
hippocampus (shrinkage) that lead to (iii) amygdala
dominance of the hypothalamus, causing (iv) more
emotional and SNS-focussed behavioural activity pat-
terns, can be understood as a chain of neuro-beha-
vioural responses to threat that may possess some
immediate benefit for the individual exhibiting them.
Concomitantly to these adjustments to uncontrollable
stress, emotional responses to such adversity engender
some typical physiological responses including crying
[37], an activity which secretes endorphins, thereby
providing some relief from the depression, however
transient [110]. Other physiological responses observed
during depression include sleepiness (which provides
respite from awareness of the aversive environmental
stimuli), and compensatory behaviours such as over-
eating (which may be distracting and/or pleasant)
[37,107]. Coupled with apathy, reduced interest or
pleasure in activities relating to the stressful environ-
ment, and overall social and behavioural withdrawal,
these observable phenomena comprise the major
symptomatology of MDD.
Using a behavioural-brain model in therapy:
Implications for treatment
As well as explaining the link between aversive environ-
mental stressors, withdrawal (depressive) behaviour and
escape, plus access to valued environmental conse-
quences via functional analysis as described above, the
range of behavioural therapies share the principal
effective components of (i) building rapport between
therapist and patient [111,112], and (ii) behavioural
homework activities which are recommended by thera-
pists to help patients re-experience pleasure in daily
activities [113]. Although beyond the scope of this
paper, the wide range of behaviourally-oriented thera-
pies, methods of establishing rapport and ways of
enhancing generalisation of in-therapy cognitive changes
to real-world behavioural change is recognised here. For
the purposes of the major argument being proposed
(i.e., that inclusion of neurological phenomena within
those behavioural frameworks will enable therapists to
understand how depression occurs), this wide range of
approaches is subsumed under the term “behavioural
therapies”.
If accentuated, the first of these therapeutic strategies
(i.e., therapeutic rapport) can provide a powerful one-
on-one interpersonal rapport experience for the
depressed person, and may reduce hypercortisolaemia
[107]. Support for this hypothesis comes from the find-
ing that some behavioural therapies reduce “waking cor-
tisol” [114] which is significantly associated with
depression [115]. An analogy may be drawn between the
hypercortisolemia observed in depression and that
Sharpley and Bitsika Behavioral and Brain Functions 2010, 6:73
http://www.behavioralandbrainfunctions.com/content/6/1/73
Page 5 of 9
brought about by a lack of maternal stimulation and
care given to neonates who consequently develop HPA-
axis hyperactivation [116] and are vulnerable to early-
onset depression during adolescence (although the
potential for reversal of this is shown by hippocampal
neurogenesis when maternal nurturance is reinstated
[117]). Similarly, the intense verbal support and atten-
tion that is provided during psychological therapies may
present a parallel nurturing experience for depressed
patients who may previously have lost most sources of
social reinforcement [107].
The second major strategy of behaviour therapies is
that of behavioural activation, or encouraging the
depressed person to engage in behaviours that will bring
more positive social and personal enjoyment [113]. By
replacing social-withdrawal behaviours with social-
engagement behaviours, the previously-uncontrollable
environmental stressor that instigated hypercortisolae-
mia (and its consequences to the PFC, hippocampus
and amygdala that worked to help the depressed indivi-
dual withdraw from their threatening environment),
may become less important to the person facing it and
therefore reduce the need for the accompanying (and
functional) neurobiological sequence of withdrawal
events that has been described above.
However, these neurobiological effects of behaviour
therapies are valuable but often occur without the
awareness of behaviour therapists. Based upon the links
described above between environmental stressors, neu-
robiological sequelae, and overt behaviour, several other
suggestions may be made so that behaviour therapists
might actively incorporate neurobiological data into
behaviourally-focussed therapies for depression. First, as
well as standard psychological assessment and back-
ground information, induction to therapy for depression
might include blood or saliva tests for hypercortisolae-
mia as an indicator of prolonged HPA activation that
may lead to organic changes to the PFC, hippocampus
and amygdala. Although more invasive, functional MRI
assessments of those sections of the depressed patient’s
brain might also inform initial assessment and provide a
baseline for evaluation after treatment. Second, although
considered to be an important and existing aspect of
those therapies, the level of rapport and support engen-
dered in behavioural therapies should receive major
attention because intense rapport has been shown to
decrease cortisol (as described above). Therefore, this
aspect of the patient-therapist interaction should be
more than the superficial friendliness that is part of
common professional demeanour [118-120]. Third,
many depressed patients may experience depression fol-
lowing a tragic event such as death of a loved one, job
loss, or a major personal injury that inhibits previously-
available activities. Although the DSM-IV-TR states that
depression arising from some of these events is actually
“understandable intense sadness” rather than clinical
depression [37], patients’ feelings are real to them and
may be experienced by them as depression. By having
the functional value of the neurobiological events that
are detailed in this paper explained to them during ther-
apy, depressed patients may accept that their “depres-
sion” (i.e., social withdrawal) is functional, and thus
indicative of their overall adaptability to major loss
rather than of mental illness. Fourth, although the beha-
vioural activation aspect of therapy (i.e., via homework
in the real world) is a significant factor in patient
change under those therapeutic approaches [113],
emphasis on the beneficial effects of those activities that
are designed to help patients expose themselves to mul-
tiple sources of distraction and social nurturance might
be augmented by explanations of how they can poten-
tially re-establish normal HPA axis activation, reduce
serum cortisol levels, renew PFC and hippocampal
neurogenesis, and re-establish the “balance” between
emotional and rational decision-making about environ-
mental stress. Fifth, the use of behavioural coaching
may be beneficial for clients who are currently unable to
instigate self-helping behaviour that enhances their
social reinforcers.
Conclusion
Although a wealth of research data support the use of
behavioural models of depressive behaviour and beha-
vioural therapies for treatment of depression, particu-
larly those which emphasise a functional analysis
component, the neurobiological underpinnings of the
onset of depressive behaviour and its adaptive conse-
quences for the person exhibiting it (and, consequen-
tially, behavioural therapy approaches for treatment of
depression) have not been joined in a comprehensive
model. Built upon the notions of sickness behaviour as
providing a benefit to the infected organism, the conco-
mitant neurobiological alterations to structure and func-
tion of various brain regions (principally the PFC,
hippocampus and amygdala) that accompany elevated
HPA-axis activation following the onset of uncontrolla-
ble and highly aversive environmental stressors, may be
seen to link observable behaviour with brain function to
provide a more comprehensive model of depression.
Further exploration of this model via monitoring of
brain function during depressive experiences and ther-
apy may help provide more detail for this model and
move it towards greater completeness.
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